Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.
Hwail Pharmaceutical Co.Ltd (061250) - Total Assets
Latest total assets as of September 2025: ₩213.14 Billion KRW
Based on the latest financial reports, Hwail Pharmaceutical Co.Ltd (061250) holds total assets worth ₩213.14 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hwail Pharmaceutical Co.Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Hwail Pharmaceutical Co.Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hwail Pharmaceutical Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hwail Pharmaceutical Co.Ltd's total assets of ₩213.14 Billion consist of 62.1% current assets and 38.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩54.11 Billion | 25.1% |
| Accounts Receivable | ₩27.28 Billion | 12.7% |
| Inventory | ₩29.22 Billion | 13.6% |
| Property, Plant & Equipment | ₩65.58 Billion | 30.4% |
| Intangible Assets | ₩1.85 Billion | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Hwail Pharmaceutical Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hwail Pharmaceutical Co.Ltd's current assets represent 62.1% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 25.1% of total assets in 2024, up from 4.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 30.4% of total assets.
Hwail Pharmaceutical Co.Ltd Competitors by Total Assets
Key competitors of Hwail Pharmaceutical Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Hwail Pharmaceutical Co.Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Hwail Pharmaceutical Co.Ltd generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Hwail Pharmaceutical Co.Ltd generates $ 3.01 in net profit.
Hwail Pharmaceutical Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 25.62 | 12.19 | 8.61 |
| Quick Ratio | 20.94 | 9.44 | 5.79 |
| Cash Ratio | 0.00 | 5.60 | 0.00 |
| Working Capital | ₩123.36 Billion | ₩ 118.74 Billion | ₩ 94.03 Billion |
Hwail Pharmaceutical Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Hwail Pharmaceutical Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.43 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 15.9% |
| Total Assets | ₩215.61 Billion |
| Market Capitalization | $13.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hwail Pharmaceutical Co.Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hwail Pharmaceutical Co.Ltd's assets grew by 15.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hwail Pharmaceutical Co.Ltd (2011–2024)
The table below shows the annual total assets of Hwail Pharmaceutical Co.Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩215.61 Billion | +15.92% |
| 2023-12-31 | ₩186.00 Billion | +0.22% |
| 2022-12-31 | ₩185.60 Billion | -4.40% |
| 2021-12-31 | ₩194.15 Billion | +14.42% |
| 2020-12-31 | ₩169.68 Billion | +21.72% |
| 2019-12-31 | ₩139.40 Billion | +12.96% |
| 2018-12-31 | ₩123.41 Billion | -0.40% |
| 2017-12-31 | ₩123.90 Billion | -3.66% |
| 2016-12-31 | ₩128.62 Billion | -8.31% |
| 2015-12-31 | ₩140.27 Billion | +14.11% |
| 2014-12-31 | ₩122.92 Billion | -0.08% |
| 2013-12-31 | ₩123.02 Billion | +8.74% |
| 2012-12-31 | ₩113.14 Billion | +14.60% |
| 2011-12-31 | ₩98.73 Billion | -- |